Compare AARD & INGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AARD | INGN |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | 753 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.7M | 136.1M |
| IPO Year | 2025 | 2013 |
| Metric | AARD | INGN |
|---|---|---|
| Price | $5.36 | $5.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $15.29 | $11.25 |
| AVG Volume (30 Days) | 134.1K | ★ 245.6K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.11 | ★ 43.42 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $348,668,000.00 |
| Revenue This Year | N/A | $8.03 |
| Revenue Next Year | N/A | $7.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.86 |
| 52 Week Low | $3.35 | $5.06 |
| 52 Week High | $17.94 | $9.13 |
| Indicator | AARD | INGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 31.90 |
| Support Level | $4.91 | N/A |
| Resistance Level | $6.01 | $6.73 |
| Average True Range (ATR) | 0.59 | 0.15 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 47.51 | 19.59 |
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.